On November 6, 2018, the launch conference of the water adjuvant porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine developed over 8 years was grandly held in Luoyang. This water adjuvant porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine was developed by Luoyang Huizhong Biotechnology Co., Ltd. relying on the National Veterinary Medicine Engineering Technology Research Center.

Luoyang Huizhong Biotechnology Co., Ltd. is a wholly-owned subsidiary of Plyco Bioengineering Co., Ltd., a leader in domestic animal protection technology innovation. It was established in 2011 and has been successfully operated in Luoyang Huizhong Veterinary Medicine for 20 years. Plyco Bio has successfully operated Born on the basis of 10 years, it passed the GMP acceptance of the Ministry of Agriculture in May 2015. Mainly engaged in the research and development, production and operation of veterinary biological products and drugs, it is a high-tech enterprise, and its innovation ability and comprehensive strength are among the best in the industry. Huizhong Biotechnology has always adhered to the development concept of "innovation to achieve the future, decent and stable operation", relying on the scientific research platform of the National Veterinary Medicine Engineering Technology Research Center to realize the transformation of scientific and technological achievements.

Huizhong Biotechnology has successively obtained 8 national new veterinary drug certificates and more than 6 national invention patent authorizations. Successively developed the new-flow method triple inactivated vaccine known as the "one-day-old immunization expert", the domestic water adjuvant porcine circovirus type 2 and mycoplasma pneumonia double inactivated vaccine, which has contributed to the technological advancement of my country's veterinary drug industry and animal Disease prevention and control and animal product safety provide excellent technical and product support.

The "Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae Dual Inactivated Vaccine" that is listed this time is Huizhong Biotechnology Co., Ltd. adhering to the business philosophy of "decent and stable operation" and pursuing the development strategy of "innovation for the future". Relying on the major scientific and technological achievements made by the National Veterinary Drug Engineering Technology Research Center as a technology platform, it has independent intellectual property rights and has obtained the national new veterinary drug registration certificate. This result is another masterpiece obtained through continuous innovative practice since Huizhong's biological adjuvant porcine circovirus type 2 inactivated vaccine (SH strain II)!

Huizhong Biological Water Adjuvant Porcine Circovirus Type 2 Inactivated Vaccine (SH strain II), leading the domestic water adjuvant whole virus inactivated vaccine, has played a major role in the prevention and control of my country's porcine circovirus disease since the product was successfully launched , Creating good economic and social benefits; relying on the National Veterinary Medicine Engineering Technology Research Center, the company continues to conduct research and development and technological innovation and upgrades for the prevention and control of the epidemic, and develops newer and safer vaccines.

The project team used special water adjuvants and advanced seedling production technology to effectively avoid the risks of adjuvant, antigen incompatibility, stability and uniformity after single seedlings were mixed, and successfully isolated, evaluated and screened Mycoplasma strains with good immunogenicity and growth. Developed a safe and efficient water-based adjuvant suitable for two antigens, solved the three major technical problems of compatibility between PCV2 and mycoplasma antigens, and successfully developed the domestic water adjuvant porcine circovirus type 2 and mycoplasma hyopneumoniae Inactivated vaccine. The successful development and listing of this product is of great practical significance for promoting technological progress and product upgrades in the industry, and improving the level of disease prevention and control.

Background of the project:

Porcine circovirus type 2 (PCV2) can cause multiple system failure syndrome (PMWS) in weaned piglets, porcine dermatitis and nephrotic syndrome (PDNS), porcine respiratory complex disease (PRDC), sow reproductive disorder (PRF), piglet A series of diseases such as congenital tremor (CT), which are easily mixed with other pathogens or lead to secondary infections, increase the clinical complexity, thereby causing huge economic losses to pig farms and serious impacts on the global pig industry .

Mycoplasma hyopneumoniae is a chronic respiratory disease caused by infection with Mycoplasma hyopneumoniae. It is also known as "swine asthma" or "swine endemic pneumonia". After Mycoplasma hyopneumoniae enters the respiratory tract of pigs, the gradual colonization infection causes severe inflammatory damage. Part of the lung area shows fleshy, hardened and necrotic, resulting in lung dysfunction, breathing difficulties, and a decline in feed conversion rate. Piglets have a lot of infections. The disease has the characteristics of high infection rate and high infectivity, which brings huge economic losses to the world's pig industry.

In recent years, with the continuous deepening of my country’s agricultural and animal husbandry industrialization reforms, it has facilitated the sustainable development of my country’s animal husbandry. The species and number of livestock and poultry have increased significantly, and the types and frequency of livestock and poultry diseases have also increased. greatly increase. In clinical morbidity, mixed infection is a common phenomenon, especially the mixed infection of circovirus type 2 and Mycoplasma hyopneumoniae is more common. Therefore, the combined vaccine that can prevent multiple diseases is the current development trend of veterinary biological products, and it is also a breeding enterprise. Urgently needed products. Although there are mature commercial vaccines for the prevention and control of these two pathogens, there are many types and complicated immune procedures. Therefore, the combined vaccine of circovirus type 2 and Mycoplasma hyopneumoniae can make up for the single vaccine in the application process. A series of shortcomings achieve the effect of one needle and two defenses, saving time and effort.

Product advantages:

Porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine, with completely independent intellectual property rights, is the first to complete product development and obtain a new veterinary drug certificate; special water adjuvants combined with advanced vaccine production technology to ensure the quality of the combined vaccine, one shot and two defenses Effectively avoid the risks of adjuvant, antigen incompatibility, poor stability and uniformity after single vaccine mixing.

1. Domestic isolated bacterial strains are more suitable for Chinese pig farms: Mycoplasma hyopneumoniae is selected domestically isolated popular strain HN0613. The nucleotide sequence analysis of the P97 gene R1 region shows that its homology rate with domestic isolated strains is much higher than that of foreign strains. Laboratory immune challenge and clinical use have proved that it has good immunogenicity and protection, more comprehensive protection, and more suitable for Chinese pig farms.

2. Antigen purification has no interference and solves compatibility problems: By optimizing the medium formula and fermentation parameters, it has broken through the process problems of mycoplasma high-density fermentation, and the culture level has reached a stable level of 5.0×109.0 CCU/ml. Through purification processes such as tangential flow ultrafiltration, the porcine circovirus type 2 antibody in the pig serum required for mycoplasma culture is completely removed, and the removal rate of contaminated proteins reaches 99%, which avoids interference with the immune effect of circovirus and solves the problem. Compatibility of the two antigens is difficult; PK15-B1 susceptible clonal cells are used to culture ring antigen, and the culture titer is ≥1.0×107.0TCID50/head. Through purification processes such as tangential flow ultrafiltration, the removal rate of contaminated proteins has reached more than 99%, and the antibody titer in the pig serum after immunization is equivalent to that of the imported vaccine.

3. Special water adjuvant is preferred, and dual antigens are suitable at the same time: The adjuvant of this product (FreemixTM-Gel adjuvant) uses colloidal polymer cross-linked copolymer as the material to prepare nano-microspheres with positive charge on the surface, which is adsorbed by static electricity. , It can effectively adsorb negatively charged PCV2 and mycoplasma antigens, and the adjuvant antigen complexes formed are easy to be recognized and processed by immune cells; more than 90% of the nanoparticles are within 1000 nanometers in diameter, which is easy to be quickly recognized by antigen-presenting cells, start and Activate a comprehensive immune response to ensure rapid immune protection after vaccine immunization; the interior of the nanoparticle is a spatial network structure, two antigens are chimeric in it, so as to achieve a long-term sustained release, and the immunity lasts for more than 4 months.

Economic and social benefits:

The approval of the new veterinary drug for porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine is the result of Huizhong Biological’s continuous emphasis on technological innovation and increased investment in research and development. It further reflects the company’s innovative strength and also promotes the industry’s pig The upgrading of vaccine products has enriched the company’s product categories, maintained the company’s leading position in porcine circovirus vaccine innovation, and effectively enhanced the company’s overall competitiveness in the industry, which will bring new growth points for the company. .

Porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine is a new technology product used to prevent related diseases caused by porcine circovirus type 2 and Mycoplasma hyopneumoniae with the help of special water adjuvants and advanced vaccine production technology. After the product goes on the market, it will accelerate the swine vaccine industry to enter the era of joint vaccines. While further strengthening Huizhong's competitive advantage in the swine vaccine market, it will lead the technological advancement of my country's animal vaccine industry, and contribute to the prevention and control of animal diseases in our country and the production of safe animal products. Provide strong technical and product support.

Technical support unit: Overview of National Engineering Technology Research Center for Veterinary Medicines

The National Engineering Technology Research Center for Veterinary Medicines is an industry public technology research and development platform approved by the Ministry of Science and Technology and relying on Preco. The center has a research and development laboratory and a supporting animal center with an area of ​​more than 18,000 square meters. It has multiple research institutes for animal vaccines, diagnostic reagents, bioengineering, process technology, and animal drugs. It has a national-level enterprise technology center, and the development of diagnostic reagents and vaccines for animal infectious diseases. National and local joint engineering laboratories, post-doctorate workstations, academician workstations and international excellent research and development and supporting facilities. Established an excellent R&D team of more than 200 people led by Dr. Tian Kegong, Director of the World Organization for Animal Health's Reference Laboratory of Highly Pathogenic Swine Blue Ear Disease And the strength of engineering research and development.

In the past three years, the center's R&D investment has accounted for more than 10% of the company's sales revenue. It has a domestic priority and an international advanced level in genetic engineering vaccine technology, multi-linked multivalent vaccine technology, high-throughput diagnostic reagent technology and chemical raw material drug synthesis technology!